echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > OMCL: The impact of metformin pre-stroke on the 1-year prognosis of type 2 diabetic patients with cerebral hemorrhage

    OMCL: The impact of metformin pre-stroke on the 1-year prognosis of type 2 diabetic patients with cerebral hemorrhage

    • Last Update: 2021-11-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Background: Metformin is the first-line drug for the treatment of type 2 diabetes


    Metformin treatment can reduce the level of oxidative stress in patients with type 2 diabetes


    Upon admission, record demographic information (age, gender, race/ethnicity, body mass index (BMI), province), comorbidities and risk factors (smoking, drinking, diabetes course, hypertension, dyslipidemia, atrial fibrillation, coronary heart disease, Coagulation disorders, hyperhomocysteinemia, family history of stroke and transient ischemic attack [TIA]), pre-stroke (antihypertensive, antiplatelet drugs, statins, insulin therapy and metformin therapy) and acute Period treatment


    Results: We included 730 patients for analysis (median age: 65 years [IQR, 56-72] years, 57.


    The median hematoma volume of MET(+) patients was lower than that of the MET(-) group .


    Figure 1 Baseline cerebral hemorrhage in patients with MET(+) and MET(-)


    Figure 1 Baseline cerebral hemorrhage in patients with MET(+) and MET(-)


    Table: Discharge and follow-up of patients with cerebral hemorrhage


    Table: Discharge and follow-up of patients with cerebral hemorrhage


    Figure 2 Kaplan Meier curve of 1-year all-cause mortality of patients using MET (n=241) and patients not using MET (n=358)


    Figure 2 Kaplan Meier curve of 1-year all-cause mortality of patients using MET (n=241) and patients not using MET (n=358)


    Figure 3 The MRS scores of the survivors within 1 year after admission were stratified by MET usage


    Figure 3 The MRS scores of the survivors within 1 year after admission were stratified by MET usage


    In patients with diabetic intracerebral hemorrhage, the use of metformin before intracerebral hemorrhage has nothing to do with hospital mortality and one-year prognosis


    Tu WJ, Zeng Q, Wang K,et al.


    Prestroke Metformin Use on the 1-Year Prognosis of Intracerebral Hemorrhage Patients with Type 2 Diabetes.


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.